Clinical Trial Update: Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial combining a peptide vaccine with temozolomide for metastatic melanoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Temodar (Temozolomide)
• peptide vaccine

Snippet

Sponsor: Inge Marie Svane | Conditions: Malignant Melanoma | Phase 2 | Status: TERMINATED